Clinic of Dermatology, Department of Venerology, University Hospital Essen, Essen, Germany.
HIV Unit, Hospital Clinic of Barcelona, Barcelona, Spain.
Future Microbiol. 2024;19(15):1273-1282. doi: 10.1080/17460913.2024.2391190. Epub 2024 Sep 4.
WHAT IS THIS SUMMARY ABOUT?: This is a summary of an article about an ongoing study called the BICSTaR study.The BICSTaR study includes people with HIV (human immunodeficiency virus) who are taking a medicine called bictegravir/emtricitabine/tenofovir alafenamide (shortened to B/F/TAF). B/F/TAF is a single tablet that contains 3 different drugs for the treatment of HIV. The drugs work together to reduce the levels of HIV so that the virus can no longer be detected by a blood test.People taking part in the study are adults with HIV living in Europe, Canada, Israel, Japan, South Korea, Singapore and Taiwan. People take 1 tablet of B/F/TAF once a day. They are either taking B/F/TAF as their first treatment for HIV, or they have switched to B/F/TAF from another HIV treatment.Researchers looked at how well B/F/TAF worked and how safe it was in people who took B/F/TAF for a year.
WHAT ARE THE KEY TAKEAWAYS?: Researchers found that B/F/TAF worked well in almost all people in the study by reducing levels of HIV in the blood. The virus could not be found in the blood of more than 9 out of 10 (94%) people who were taking B/F/TAF as their first HIV medicine and more than 9 out of 10 people (97%) who had taken another HIV medicine before starting B/F/TAF. This is known as having an 'undetectable viral load' and is a major goal for HIV treatment success. Researchers did not find any evidence of HIV developing resistance to B/F/TAF, which might stop B/F/TAF from working properly.Around 1 out of 10 people (13%) had side effects (any unwanted sign or symptom that people have when taking a medicine that researchers think might be caused by the medicine) that might have been caused by B/F/TAF. Most of these side effects were not classified as serious. Less than 1 out of 100 (0.1%) people had serious side effects that might have been caused by B/F/TAF. Only 6 out of 100 people stopped taking B/F/TAF due to side effects caused by B/F/TAF. As a result, more than 9 out of 10 people (95%) took B/F/TAF for at least 1 year.
WHAT WERE THE MAIN CONCLUSIONS REPORTED BY THE RESEARCHERS?: B/F/TAF worked well in people with HIV in this study. Most people (around 9 out of 10) did not have any side effects.
这是一篇关于正在进行的 BICSTaR 研究的文章摘要。BICSTaR 研究包括正在服用一种名为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺（简称 B/F/TAF）的药物的 HIV（人类免疫缺陷病毒）感染者。B/F/TAF 是一种含有 3 种不同药物的单片制剂，用于治疗 HIV。这些药物协同作用降低 HIV 水平，使病毒无法通过血液检测到。参与研究的是在欧洲、加拿大、以色列、日本、韩国、新加坡和中国台湾居住的 HIV 感染者成年人。他们每天服用 1 片 B/F/TAF。他们要么首次接受 B/F/TAF 治疗 HIV，要么从其他 HIV 治疗方案转为 B/F/TAF 治疗。研究人员观察了 B/F/TAF 在服用一年的人群中的疗效和安全性。
研究人员发现，B/F/TAF 在研究中的绝大多数人身上效果良好，通过降低血液中的 HIV 水平。接受 B/F/TAF 作为首种 HIV 药物治疗的人群中，有超过 9 成（94%）的人病毒载量无法检测到，而在开始接受 B/F/TAF 治疗前曾接受过其他 HIV 药物治疗的人群中，有超过 9 成（97%）的人病毒载量无法检测到。这被称为“病毒载量不可检测”，是 HIV 治疗成功的主要目标。研究人员没有发现 HIV 对 B/F/TAF 产生耐药性的证据，这可能会导致 B/F/TAF 无法正常发挥作用。约每 10 人中有 1 人（13%）出现了副作用（在服用药物后出现的任何研究者认为可能由药物引起的、不希望出现的体征或症状），可能是由 B/F/TAF 引起的。这些副作用大多不属于严重级别。不到 100 人中就有 1 人（0.1%）出现了严重副作用，可能是由 B/F/TAF 引起的。仅有 6 人（6%）因 B/F/TAF 引起的副作用而停止服用 B/F/TAF。结果，超过 9 成（95%）的人至少服用了 1 年的 B/F/TAF。
研究人员报告的主要结论是什么？在这项研究中，B/F/TAF 对 HIV 感染者效果良好。大多数人（约 9 成）没有任何副作用。
